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The sphingosine-
phosphate signaling 
pathway in acute renal 
failure
Endothelial injury with consequent 
activation of infl ammatory mediators is 
one of the major causes of renal failure 
in ischemic renal injury. Endothelial 
cell integrity is maintained by many 
factors, one of which is the production 
of the signaling molecule sphingosine-
1-phosphate (S1P). Th is lipid mediator 
binds to a class of receptors, fi ve of 
which exist in the mammalian genome. 
Activation of the ubiquitous S1P 
receptor 1 (S1P1) maintains endothelial 
integrity and prevents migration of 
lymphocytes and monocytes across the 
endothelial barrier. Recently, a newly 
identifi ed small molecule (SEW2871), 
which was found to act as an S1P1 
agonist, has allowed for testing of the 
function of this receptor in a variety of 
systems. Lien et al. tested the role of this 
system in the pathogenesis of ischemic 
injury in mice. Th ey generated transient 
ischemia in these animals and harvested 
their kidneys aft erward. Th ey found that 
pretreatment of the animals with the 
S1P1 agonist improved renal function 
and decreased creatinine levels to lower 
than those of controls. Histological 
analysis also showed improvement of 
renal structures. Recent studies suggest 
that invasion of the renal parenchyma 
by lymphocytes and macrophages is an 
important element in the pathogenesis 
of renal damage in acute ischemic injury. 
Lien et al. showed that activation of the 
S1P1 receptor drastically reduced the 
presence of these infl ammatory cells in 
the renal parenchyma aft er ischemia. 
Endothelial damage was associated 
with the induction of tumor necrosis 
factor-α, and the adhesion molecules 
P-selectin, E-selectin, and intercellular 
adhesion molecule-1. Th ese studies 
suggest that activation of the S1P 
pathway off ers potential as a protective 
strategy in the management of renal 
ischemia. See page 1601.
Renal pathology 
of idiopathic 
membranous 
nephropathy
Idiopathic membranous nephropathy 
(MGN) is one of the more common 
causes of renal disease, with a variable 
rate of progression toward renal failure. 
Hence, there is a need to fi nd early 
predictors of progression to guide 
immunosuppressive therapy. In a study 
reported in this issue, Troyanov et al. 
examined renal biopsies of 389 patients 
with MGN and tested for an association 
between the detailed pathological 
fi ndings and the rate of renal decline and 
other clinical parameters. Th ey found 
that patients with tubulo-interstitial 
disease, vascular sclerosis, or focal and 
segmental glomerulosclerosis (FSGS) 
lesions were older and presented with 
a higher mean arterial pressure and 
a lower creatinine clearance. Despite 
the fact that these histological features 
were associated with a higher rate of 
progression to renal failure, they did 
not independently predict MGN, nor 
did they correlate with the rate of renal 
decline or with baseline proteinuria. 
In addition, although it is typically 
thought that severe tubulo-interstitial 
and vascular lesions predict renal 
failure, many patients responded to 
immunosuppressive therapy despite 
having FSGS. Th ese results provide a 
complex picture of this puzzling and 
common disease; although histology 
is associated with progression to renal 
failure, the indicators of chronic injury 
are primarily associated with age, blood 
pressure, and creatinine clearance at 
presentation rather than with rate of 
disease progression. See page  1641.
Receptors for prorenin 
and renin
Considering that intensive studies of 
the renin–angiotensin system have been 
going on for almost 50 years, it is hard to 
imagine that one could discover anything 
new about it. Yet, it has been shown 
that local production of renin allows 
for the generation of angiotensin that is 
independent of the circulating hormone. 
Th is implies that angiotensinogen 
must also either be made or be trapped 
locally. Recently, it was found that renin 
and prorenin can bind to some cells 
and activate a signaling cascade. In this 
issue, Nguyen et al. describe the hunt for 
these receptors. Th e authors identifi ed 
two receptors, both binding to renin 
and prorenin. One, to the mannose-
6-phosphate receptor (M6P-R), is well 
known. Th e other, a specifi c receptor, is 
less known and has not been found to 
bind to any other ligand. M6P-R caused 
internalization, followed by intracellular 
proteolysis of prorenin to renin. But as it 
did not seem to generate any intracellular 
angiotensins, it could be a clearance 
receptor. Th e specifi c receptor bound 
prorenin, which immediately showed 
increased catalytic activity, suggesting 
that the binding caused a conformational 
change. Remarkably, this binding led 
to intracellular signaling by activation 
of mitogen-activated protein kinases 
without the generation of angiotensin. 
Transgenic overexpression of this 
receptor in vascular smooth muscle cells 
led to hypertension, and generalized 
overexpression led to glomerulosclerosis. 
Th e paper discusses the interesting 
implications of this new receptor 
system in the pathogenesis of prorenin, 
especially in situations with low renin 
and high prorenin concentrations, such 
as in diabetes. See page 1503.
